Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Full text links

Actions

.2016 Feb 15;196(4):1480-7.
doi: 10.4049/jimmunol.1501721. Epub 2016 Jan 18.

The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference

Affiliations

The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference

Thomas Trolle et al. J Immunol..

Abstract

HLA class I-binding predictions are widely used to identify candidate peptide targets of human CD8(+) T cell responses. Many such approaches focus exclusively on a limited range of peptide lengths, typically 9 aa and sometimes 9-10 aa, despite multiple examples of dominant epitopes of other lengths. In this study, we examined whether epitope predictions can be improved by incorporating the natural length distribution of HLA class I ligands. We found that, although different HLA alleles have diverse length-binding preferences, the length profiles of ligands that are naturally presented by these alleles are much more homogeneous. We hypothesized that this is due to a defined length profile of peptides available for HLA binding in the endoplasmic reticulum. Based on this, we created a model of HLA allele-specific ligand length profiles and demonstrate how this model, in combination with HLA-binding predictions, greatly improves comprehensive identification of CD8(+) T cell epitopes.

Copyright © 2016 by The American Association of Immunologists, Inc.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Peptide binding length preference for five common HLA alleles
The length preference for each HLA was determined by measuring the binding affinity of a series of fixed C-terminal combinatorial libraries of different length. Three series were tested, with either I, K or F at the C-terminal. The series with the strongest binding affinity was selected to represent the HLA allele. The selected series is denoted in the parentheses in the legend. IC50 binding affinities for each length were calculated as geometric means of 3-6 experiments. The relative binding affinities plotted were calculated as IC50(9)/IC50(L) where L is the peptide length. Error bars indicate standard errors of the geometric means.
Figure 2
Figure 2. Length profiles of naturally presented peptides for five HLA molecules
Large datasets of HLA-I ligands were determined by the elution of ligands from secreted HLAs followed by mass spectrometry identification of the peptide sequences. From these ligand datasets, the number of ligands of each length was totaled. The y-axis indicates the number of ligands identified for a given length normalized by the number of peptides identified for the HLA at length 9.
Figure 3
Figure 3. Model fit of the available peptide length profile
The available peptide length profile was fitted using MHC ligand length profiles and HLA binding length preferences for HLA-A*01:01, HLA-A*02:01, HLA-A*24:02, HLA-B*07:02 and HLA-B*51:01 as described in the Materials and Methods. The optimal value for β associated with the fit was 0.30.
Figure 4
Figure 4. Predicted vs. measured ligand length profiles for five HLA molecules
A leave-one-out training was carried out by removing an HLA from the training dataset and then fitting the available peptide length profile with the remaining four HLAs. The resulting available peptide length profile was used in conjunction with the removed HLA’s binding length preference (Fig. 1) to predict the removed HLA’s ligand length profile. This predicted length profile was then compared to the measured ligand length profile of the removed HLA. As an example, in the HLA-A*01:01 plot, HLA-A*01:01 data was not used to fit an available peptide length profile (not shown). This available peptide length profile was then combined with the HLA-A*01:01 binding length preference to determine the predicted ligand length profile (blue line). This profile was compared to the measured HLA-A*01:01 ligand length profile (red line).
Figure 5
Figure 5. Benchmarks of T cell epitope and MHC-I ligand predictions
For each benchmark dataset, source proteins for each of the epitopes/ligands were downloaded and split into overlapping peptides of various lengths. The lengths of the overlapping peptides were determined by the lengths of the epitopes/ligands in the benchmark datasets; 8-13mer overlapping peptides for the IEDB, Marcilla and Thommen datasets, and 8-11mers for the Granados dataset. For each dataset, three sorted peptide lists were created using the following approaches: 1) predict affinities for all overlapping peptides and rank them based on their predicted IC50 value without taking length into account, 2) predict affinities for all 9mer peptides and rank them based on their predicted IC50 values (peptides of other lengths are considered non-candidates), 3) predict length corrected binding affinities for all overlapping peptides using the novel method described here and rank the peptides based on length corrected predictions. The plots show the number of epitopes/ligand identified by each approach as a function of the number of peptides tested, had the peptides been selected using the sorted lists described above.
See this image and copyright information in PMC

References

    1. Peters B, Bui H-H, Frankild S, Nielson M, Lundegaard C, Kostem E, Basch D, Lamberth K, Harndahl M, Fleri W, Wilson SS, Sidney J, Lund O, Buus S, Sette A. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput. Biol. 2006;2:e65. - PMC - PubMed
    1. Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol. 2008;9:8. - PMC - PubMed
    1. Zhang GL, Ansari HR, Bradley P, Cawley GC, Hertz T, Hu X, Jojic N, Kim Y, Kohlbacher O, Lund O, Lundegaard C, a Magaret C, Nielsen M, Papadopoulos H, Raghava GPS, Tal V-S, Xue LC, Yanover C, Zhu S, Rock MT, Crowe JE, Panayiotou C, Polycarpou MM, Duch W, Brusic V. Machine learning competition in immunology - Prediction of HLA class I binding peptides. J. Immunol. Methods. 2011;374:1–4. - PubMed
    1. Trolle T, Metushi IG, Greenbaum JA, Kim Y, Sidney J, Lund O, Sette A, Peters B, Nielsen M. Automated benchmarking of peptide-MHC class I binding predictions. Bioinformatics. 2015;31:2174–2181. - PMC - PubMed
    1. Erup Larsen M, Kloverpris H, Stryhn A, Koofhethile CK, Sims S, Ndung’U T, Goulder P, Buus S, Nielsen M. HLArestrictor - a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics. 2011;63:43–55. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp